title: Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease.
abstract: Recombinant vector systems have been recently identified that when delivered systemically can transduce neurons, glia, and endothelia in the central nervous system (CNS), providing an opportunity to develop therapies for diseases affecting the brain without performing direct intracranial injections. Vector systems based on adeno-associated virus (AAV) include AAV serotype 9 (AAV9) and AAVs that have been re-engineered at the capsid level for CNS tropism. Here, we performed a head-to-head comparison of AAV9 and a capsid modified AAV for their abilities to rescue CNS and peripheral disease in an animal model of lysosomal storage disease (LSD), the mucopolysacharidoses (MPS) VII mouse. While the peptide-modified AAV reversed cognitive deficits, improved storage burden in the brain, and substantially prolonged survival, we were surprised to find that AAV9 provided no CNS benefit. Additional experiments demonstrated that sialic acid, a known inhibitor of AAV9, is elevated in the CNS of MPS VII mice. These studies highlight how disease manifestations can dramatically impact the known tropism of recombinant vectors, and raise awareness to assuming similar transduction profiles between normal and disease models.
authors.affiliation: Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA.
authors.forename: Yong Hong
authors.initials: YH
authors.lastname: Chen
authors.forename: Kristin
authors.initials: K
authors.lastname: Claflin
authors.forename: James C
authors.initials: JC
authors.lastname: Geoghegan
authors.forename: Beverly L
authors.initials: BL
authors.lastname: Davidson
mesh_terms: D000818:Animals; D001921:Brain; D036022:Capsid Proteins / Q000235:genetics; D000229:Dependovirus / Q000235:genetics*; D004195:Disease Models, Animal; D015316:Genetic Therapy; D005822:Genetic Vectors; D051379:Mice; D008822:Mice, Transgenic; D016538:Mucopolysaccharidosis VII / Q000235:genetics / Q000628:therapy*; D019158:N-Acetylneuraminic Acid / Q000378:metabolism*
chemical_list: D036022:Capsid Proteins; D019158:N-Acetylneuraminic Acid